NCT04604795View on ClinicalTrials.gov

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GSK3915393 in Healthy Participants and to Evaluate the Interaction Between GSK3915393 and Grapefruit Juice and Itraconazole

PHASE1CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

November 4, 2020

Primary Completion Date

June 29, 2021

Study Completion Date

June 29, 2021

Conditions
Celiac DiseaseCoeliac Disease
Interventions
DRUG

GSK3915393 Capsules

GSK3915393 capsules will be given orally.

DRUG

GSK3915393 Solution for Infusion

GSK3915393 solution for infusion will be administered intravenously.

DRUG

Placebo capsules

Placebo matching GSK3915393 capsules will be given orally.

DRUG

Itraconazole

Participants will be administered with GSK3915393 along with ITZ orally

OTHER

Water

Participants will be administered with GSK3915393 along with water orally

OTHER

Grape fruit juice

Participants will be administered with GSK3915393 along with GFJ orally

Trial Locations (1)

NW10 7EW

GSK Investigational Site, London

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT04604795 - Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GSK3915393 in Healthy Participants and to Evaluate the Interaction Between GSK3915393 and Grapefruit Juice and Itraconazole | Biotech Hunter | Biotech Hunter